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Conclusions: 1. A close follow-up policy
enables detection the second breast
cancer at an earlier stage than the primary
one. 2. SBBC and MBBC seem to be
different set of tumors in term of clinical
characteristics and survival.
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CD4+ and CD8+ T lymphocytes from the
peripheral blood of melanoma patients are
prone to undergo spontaneous apoptosis
when compared with healthy individuals.
The rapid lymphocyte turnover and the
loss of CD4+ and CD8+ T cells may cause
the weak antitumor response in cancer
patients. Since CD4+ and CD8+ T cell
mediated immune responses play an
important role in controlling the antitumor
response, enhancing the survival and
function of these T cells may improve the
disease outcome of melanoma patients. In
our experiment, we tried to see the effect
of interleukin 15 (IL-15) on the spon-
taneous apoptosis of peripheral blood
mononuclear cells (PBMCs) from patients
with melanoma. The PBMCs obtained
from 16 melanoma patients and 16 healthy
controls were incubated overnight in
medium with or without IL-15: The PBMCs
were then stained for CD4+ or CD8+ cells
and evaluated for apoptosis with the
Annexin V binding method using a
multicolor flow cytometry. The results
showed that IL-15 inhibits spontaneous
apoptosis in CD4+ and CD8+ T cells in
both melanoma patients and healthy
individuals. IL-15 significantly reduced
6.3% (mean±spontaneous apoptosis of
CD8+ T-cells in melanoma patients from
26 8.7% (n=16, P± SO) to 19 ±< 3.4%
to±0.005) and in healthy controls from 15
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3.4% (n=16, P±11 <0.005). There was a
similar result with CD4+ cells with 7.3%±
6.7% to 17 ±IL-15 reducing the apoptosis
in melanoma patients from 22 (n=16, P<
4.0% (n=16,± 4.1 % to 9 ±.005) and in
healthy controls form 12 P<.005). IL-15
may thus prove useful in a therapeutic
immunostimulation strategy for melanoma
patients
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Malignant melanoma is resistant, except
for a small percent, to treatments such as
radio and chemotherapy. On the other
hand melanoma has been considered as
the prototypical immunogenic tumor in
which the immune system may have a role
in the outcome of the disease. Immune
cells from cancer patients respond poorly
to mitogenic or antigenic stimuli. One
reason for this is the rapid turn over of the
T lymphocytes arising from the apoptosis
of these cells. The induction of apoptosis
in the activated T lymphocytes is
considered as one of the ways the tumor
cells avoid recognition and destruction.
The Fas (APO-1, CD95)/FasL pathway is
well know to induce apoptotic cell death
in many cells. In this study the expression
of Fas and its correlation withapoptosis
on CD4+ and CD8+ T cells in PBMCs from
melanoma patients was measured.
Annexin V was used to measure apo-
·ptosis. For the present study, we obtained
5ml of venous blood from 16 pa-tients and
10 healthy controls. The lymphocytes were
then isolated using the Ficoll-Hypaque
gradient centrifugation. The lymphocytes
were then incubated in medium for 24hrs
and then stained with PerCP-labled
monoclonal antibodies of anti CD4 or anti
CD8. They were then washed and stained
S299
